Literature DB >> 16708183

Parkinson's disease and dementia.

A Padovani1, C Costanzi, N Gilberti, B Borroni.   

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders, affecting about 1% of the population over the age of 60. In addition to motor abnormalities, there are several non-motor signs and symptoms that may create a considerable burden for patients and care-givers. Dementia is common and affects approximately 40% of PD patients during the course of the disease, the risk for the development of dementia being 6 times higher than in non-PD age-matched controls. In most cases, PD patients with dementia (PDD) display a dysexecutive syndrome and visuospatial deficits, while memory is relatively unaffected. The overlap between PDD and dementia with Lewy bodies suggests that they likely share similar underlying neuropathological processes.

Entities:  

Mesh:

Year:  2006        PMID: 16708183     DOI: 10.1007/s10072-006-0546-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia.

Authors:  Mohammad Haris; Anup Singh; Kejia Cai; Christos Davatzikos; John Q Trojanowski; Elias R Melhem; Christopher M Clark; Arijitt Borthakur
Journal:  J Neurol       Date:  2010-10-07       Impact factor: 4.849

2.  Tone discrimination as a window into acoustic perceptual deficits in Parkinson's disease.

Authors:  Joshua Troche; Michelle S Troche; Rebecca Berkowitz; Murray Grossman; Jamie Reilly
Journal:  Am J Speech Lang Pathol       Date:  2012-03-21       Impact factor: 2.408

Review 3.  Animal models of the non-motor features of Parkinson's disease.

Authors:  Kimberly McDowell; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2012-01-03       Impact factor: 5.996

4.  Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

Authors:  Ki Sung Kang; Noriko Yamabe; Yujing Wen; Masayuki Fukui; Bao Ting Zhu
Journal:  Brain Res       Date:  2012-12-01       Impact factor: 3.252

5.  Patients with chronic kidney disease are at an elevated risk of dementia: a population-based cohort study in Taiwan.

Authors:  Kao-Chi Cheng; Yu-Lung Chen; Shih-Wei Lai; Chih-Hsin Mou; Pang-Yao Tsai; Fung-Chang Sung
Journal:  BMC Nephrol       Date:  2012-09-29       Impact factor: 2.388

6.  Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies.

Authors:  Ki Sung Kang; Yujing Wen; Noriko Yamabe; Masayuki Fukui; Stephanie C Bishop; Bao Ting Zhu
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

7.  Virtual multiple errands test (VMET): a virtual reality-based tool to detect early executive functions deficit in Parkinson's disease.

Authors:  Pietro Cipresso; Giovanni Albani; Silvia Serino; Elisa Pedroli; Federica Pallavicini; Alessandro Mauro; Giuseppe Riva
Journal:  Front Behav Neurosci       Date:  2014-12-05       Impact factor: 3.558

8.  Transcranial direct current stimulation enhances theory of mind in Parkinson's disease patients with mild cognitive impairment: a randomized, double-blind, sham-controlled study.

Authors:  Mauro Adenzato; Rosa Manenti; Ivan Enrici; Elena Gobbi; Michela Brambilla; Antonella Alberici; Maria Sofia Cotelli; Alessandro Padovani; Barbara Borroni; Maria Cotelli
Journal:  Transl Neurodegener       Date:  2019-01-07       Impact factor: 8.014

9.  Rivastigmine for the treatment of dementia associated with Parkinson's disease.

Authors:  Jennifer L Reingold; John C Morgan; Kapil D Sethi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  Executive cognitive tests for the evaluation of patients with Parkinson's disease.

Authors:  Emmanuelle Silva Tavares Sobreira; Marina Ceres Silva Pena; José Humberto Silva Filho; Carolina Pinto Souza; Guiomar Nascimento Oliveira; Vitor Tumas; Francisco de Assis Carvalho do Vale
Journal:  Dement Neuropsychol       Date:  2008 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.